Study guide

9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

Key Takeaways Explain This Topic AI

ECMO circuit priming with crystalloids and blood products expands circulating blood volume by 100% to 300% in neonates and young infants, dramatically expanding the apparent volume of distribution (Vd) and necessitating larger weight-based loading doses for hydrophilic antimicrobials (e.g., vancomycin, aminoglycosides, beta-lactams).

Lipophilic and highly protein-bound medications (e.g., fentanyl, midazolam, voriconazole, propofol) undergo extensive sequestration into polyvinyl chloride (PVC) circuit tubing and polymethylpentene (PMP) oxygenator membranes, causing rapid therapeutic failure unless doses or continuous infusions are substantially escalated.

Morphine (log P ~0.89) exhibits significantly less circuit adsorption than fentanyl (log P ~4.05), making it the preferred first-line opioid analgesic for neonates and pediatric patients supported on ECMO.

Systemic anticoagulation on ECMO is primarily maintained with continuous unfractionated heparin titrated to anti-factor Xa levels (0.3–0.7 units/mL) or activated clotting time (ACT 180–220 seconds); escalating heparin requirements (>40–60 units/kg/h) signal antithrombin III deficiency, requiring ATIII supplementation to maintain functional activity >80–100%.

Bivalirudin is a direct thrombin inhibitor that functions independently of antithrombin III, serving as the preferred alternative anticoagulant for heparin-induced thrombocytopenia (HIT) or intractable heparin resistance, titrated to an activated partial thromboplastin time (aPTT) of 60–80 seconds.

Last updated: September 2026

9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

Extracorporeal Membrane Oxygenation (ECMO) provides temporary, life-sustaining cardiopulmonary support for neonates, infants, and children with refractory respiratory or cardiac failure failing maximal conventional medical management. While ECMO maintains end-organ perfusion and gas exchange, introducing an extracorporeal circuit composed of large synthetic surface areas, an artificial membrane oxygenator, and a non-biological priming volume creates profound pharmacokinetic (PK) disruptions. Clinicians must adjust dosing regimens based on drug physicochemical properties to prevent therapeutic failures or severe toxicities.

Circuit Physiology: VA vs. VV ECMO Configurations ECMO Circuit Architectures:

  • [VV ECMO - Isolated Pulmonary Support] [VA ECMO - Cardiopulmonary Support]
  • Venous Drainage (IVC / Femoral V) Venous Drainage (Right Atrium / SVC)
  • │ │
  • ▼ ▼
  • [Centrifugal Pump] [Centrifugal Pump]
  • │ │
  • ▼ ▼
  • [PMP Membrane Oxygenator] [PMP Membrane Oxygenator]
  • (CO2 removed, O2 added) (CO2 removed, O2 added)
  • │ │
  • ▼ ▼
  • Venous Return (Right Atrium) Arterial Return (Aorta / Carotid A)
  • (Relies on native cardiac output) (Provides systemic perfusion & MAP)

Feature Venovenous (VV) ECMO Venoarterial (VA) ECMO

Organ Support Pulmonary support only (gas exchange: oxygenation & C O 2 CO_2 C O 2 ​ clearance) Full cardiac AND pulmonary support (circulatory perfusion + gas exchange)

Indications Refractory ARDS, meconium aspiration syndrome, persistent pulmonary hypertension (PPHN) with preserved cardiac function Refractory cardiogenic shock, failure to wean from cardiopulmonary bypass, acute viral myocarditis, E-CPR (extracorporeal CPR)

Cannulation Sites Dual-lumen bicaval cannula in right internal jugular vein; or two cannulae (femoral drainage, internal jugular return) Venous drainage via right internal jugular / right atrium; arterial return via right common carotid artery , ascending aorta, or femoral artery

Hemodynamics Native heart must pump all blood; systemic arterial waveforms remain fully pulsatile Unloads the left/right ventricles; arterial pulse pressure is dampened or non-pulsatile; circuit provides systemic blood pressure

Circuit Hardware Components

Blood Tubing: Medical-grade polyvinyl chloride (PVC) or heparin-coated polyurethane.

Blood Pump: Centrifugal pumps utilizing magnetic levitation impellers are standard; they minimize shear stress, turbulence, and red blood cell hemolysis compared to older roller pumps.

Membrane Oxygenator: Hollow-fiber polymethylpentene (PMP) diffusion membranes. PMP prevents plasma leakage across hollow fibers, provides high gas-exchange efficiency, and resists protein deposition better than historic silicone membranes.

Heat Exchanger: Integrated within the oxygenator housing to regulate core temperature.

Critical Pharmacokinetic Alterations on ECMO

Pharmacokinetic changes on ECMO are driven by two distinct mechanisms:

  • Expansion of Apparent Volume of Distribution ( V d V_d V d ​ )
  • Drug Sequestration & Adsorption into Circuit Components
  • 1. Volume of Distribution ( V d V_d V d ​ ) Expansion (Hydrophilic Drugs)

In neonates and infants, circulating blood volume is approximately 80 to 90 mL/kg (e.g., a 3 kg term neonate has a total circulating blood volume of ~250 mL). An assembled neonatal/pediatric ECMO circuit requires a priming volume of 300 to 600 mL consisting of balanced crystalloids, 5% albumin, packed red blood cells (PRBCs), and fresh frozen plasma (FFP). Circulating Blood Volume vs. Circuit Priming Volume:

  • Neonate (3 kg): [ 250 mL Native Blood ]
  • ECMO Circuit: [ ======= 350 to 500 mL Prime ======= ]
  • Total Volume: [ ================== 600 to 750 mL ================== ]
  • ▲ 150% to 200% EXPANSION OF CIRCULATING FLUID COMPARTMENT

This immediate 100% to 300% expansion of the intravascular fluid compartment dramatically dilutes circulating drug concentrations. Hydrophilic medications ( V d ≤ 0.6 L/kg V_d \le 0.6 \text{ L/kg} V d ​ ≤ 0.6 L/kg , low lipophilicity log ⁡ P < 0 \log P < 0 lo g P < 0 ) distribute extensively throughout this expanded aqueous priming volume: C peak = Dose V d C_{\text{peak}} = \frac{\text{Dose}}{V_d} C peak ​ = V d ​ Dose ​

If a standard weight-based loading dose is administered, peak serum concentrations ( C max ⁡ C_{\max} C m a x ​ ) will be severely subtherapeutic. Therefore, hydrophilic antimicrobials require significantly larger loading doses to achieve target therapeutic peaks:

Vancomycin: Loading dose increased to 25 to 30 mg/kg IV (target peak 25–35 mcg/mL; monitor via AUC/MIC or TDM troughs).

Aminoglycosides (Gentamicin/Tobramycin): Loading dose increased to 4.5 to 5 mg/kg IV in neonates (target peak 8–12 mcg/mL).

Beta-Lactams (Meropenem, Cefepime): Require maximum-tier weight-based dosing; consider extended or continuous infusions to maintain free time above MIC ( f T > MIC ≥ 70 – 100 % fT_{>\text{MIC}} \ge 70\text{--}100\% f T > MIC ​ ≥ 70 – 100% ).

2. Drug Sequestration & Circuit Adsorption (Lipophilic Drugs)

Sequestration into the ECMO circuit is primarily governed by two physicochemical parameters: lipophilicity (octanol-water partition coefficient, log ⁡ P \log P lo g P ) and plasma protein binding ( f b f_b f b ​ ) .

Mechanism: PVC tubing contains lipophilic plasticizers (e.g., DEHP), and PMP hollow fibers present a vast hydrophobic surface area. Medications with high lipophilicity ( log ⁡ P > 2.0 \log P > 2.0 lo g P > 2.0 ) and high protein binding ( > 80 % >80\% > 80% ) partition out of the aqueous plasma phase and adsorb directly into the synthetic polymers.

Consequences: Marked reduction in circulating active drug, rapid loss of clinical efficacy, and severe underdosing if conventional doses are used. Drug Partitioning in the ECMO Circuit:

  • [Hydrophilic Drugs: log P < 1.0] [Lipophilic Drugs: log P > 2.0]
  • Aminoglycosides (log P -3.1) • Fentanyl (log P +4.05)
  • Beta-Lactams (log P -1.5) • Midazolam (log P +3.90)
  • Vancomycin (log P -3.1) • Voriconazole (log P +2.56)
  • Morphine (log P +0.89) • Propofol (log P +3.80)
  • │ │
  • ▼ ▼
  • [Minimal Circuit Binding] [EXTENSIVE CIRCUIT ADSORPTION]
  • Diluted by priming fluid - Up to 80-95% loss into PVC / PMP
  • Requires HIGHER LOADING DOSE - Requires HIGHER MAINTENANCE DOSE
  • Normal clearance once loaded - Saturates over time; lost on circuit change

Medication log ⁡ P \log P lo g P Protein Binding Circuit Sequestration Clinical Action & Recommended Strategy

Fentanyl +4.05 80–85% Severe (>90% loss within 24 hours) Substantial dose escalation required (continuous infusions often exceed 5–10 mcg/kg/h). Significant tolerance and physical dependence develop rapidly.

Morphine +0.89 35% Minimal (<10–15% loss) Preferred first-line opioid on ECMO. Predictable PK profile due to low lipophilicity; does not undergo significant tubing extraction.

Hydromorphone +1.20 20% Low to Moderate Suitable alternative to morphine; significantly less circuit loss than fentanyl.

Midazolam +3.90 97% Severe (>70–80% loss) Extensive circuit binding. Requires elevated infusion rates (0.1–0.4 mg/kg/h) or transition to alternative agents (e.g., dexmedetomidine, clonidine).

Voriconazole +2.56 58% Severe (50–70% loss) Massive circuit adsorption causes unmeasurable serum troughs (<1 mcg/mL) and treatment failure. Therapeutic drug monitoring (TDM) is mandatory (target trough 2–5 mcg/mL). Echinocandins (caspofungin, micafungin) have more predictable recovery.

Propofol +3.80 98% Profound (>80% loss) Highly lipophilic lipid vehicle also dissolves plasticizers and can crack polycarbonate stopcocks; avoided in pediatrics (also carries Propofol Infusion Syndrome risk).

The "Circuit Saturation & Changeout" Phenomenon

Over the initial 48 to 72 hours of an ECMO run, binding sites on the PVC tubing and PMP membrane become progressively saturated with lipophilic drugs, and drug requirements may stabilize. However, if acute oxygenator thrombosis, membrane failure, or mechanical rupture necessitates an emergent circuit changeout , all drug binding sites are newly empty.

Important

Acute Circuit Changeout Pearl: Changing out the ECMO circuit instantly precipitates acute drug loss as the new, unsaturated tubing rapidly strips lipophilic drugs (fentanyl, midazolam) from the circulation. This induces acute sedative withdrawal and rapid drops in antimicrobial levels. Clinicians must re-bolus lipophilic sedatives and hydrophilic antibiotics immediately following circuit changeout.

Anticoagulation on ECMO: Heparin vs. Bivalirudin

Continuous blood exposure to foreign non-endothelial surfaces triggers the intrinsic coagulation cascade (Factor XII contact activation), platelet consumption, and systemic inflammation. Therapeutic anticoagulation is mandatory to prevent circuit thrombosis while avoiding catastrophic intracranial hemorrhage.

1. Unfractionated Heparin (UFH) Protocol

Mechanism: Binds to circulating Antithrombin III (ATIII) via a specific pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of Factor IIa (Thrombin) and Factor Xa by ~1,000-fold.

Dosing: Continuous IV infusion initiated at 20 to 50 units/kg/h in neonates/infants (15 to 30 units/kg/h in older children), titrated without bolus in non-bleeding patients.

Monitoring Modalities:

Anti-Factor Xa Assay (Preferred Standard): Target 0.3 to 0.7 units/mL . Anti-Xa specifically measures heparin-dependent Xa inhibition and is not confounded by hemodilution, hypofibrinogenemia, or baseline coagulopathy.

Activated Clotting Time (ACT): Target 180 to 220 seconds (bedside point-of-care test, but heavily confounded by thrombocytopenia, hemodilution, and hypothermia).

Activated Partial Thromboplastin Time (aPTT): Target 60 to 80 seconds (or 1.5 to 2.5 times patient baseline).

Heparin Resistance & Antithrombin III Management

Physiology of Heparin Resistance: Unfractionated heparin has no intrinsic anticoagulant activity —it is entirely dependent on adequate functional levels of antithrombin III. Neonatal baseline ATIII activity is only 40% to 60% of adult levels due to hepatic immaturity, and critically ill children rapidly consume ATIII through systemic inflammation and circuit contact.

Clinical Recognition: Suspect heparin resistance when the heparin infusion rate escalates beyond > 40 to 60 units/kg/h >40 \text{ to } 60 \text{ units/kg/h} > 40 to 60 units/kg/h without achieving therapeutic anti-Factor Xa ( > 0.3 units/mL >0.3 \text{ units/mL} > 0.3 units/mL ) or target ACT levels.

Target ATIII Activity: Maintain functional ATIII activity > 80 % to 100 % >80\% \text{ to } 100\% > 80% to 100% .

Antithrombin Concentrate Dosing: Administer human plasma-derived antithrombin concentrate (Thrombate III) using the formula: Antithrombin III Dose (Units) = [ Target Activity (%) − Baseline Activity (%) ] × Weight (kg) 1.4 \text{Antithrombin III Dose (Units)} = \frac{[\text{Target Activity (\%)} - \text{Baseline Activity (\%)}] \times \text{Weight (kg)}}{1.4} Antithrombin III Dose (Units) = 1.4 [ Target Activity (%) − Baseline Activity (%) ] × Weight (kg) ​

(In neonates and infants with expanded extracellular volume, some institutional protocols utilize a divisor of 1.0 to 1.2 instead of 1.4). Fresh frozen plasma (FFP) contains physiologic ATIII (1 unit/mL) but delivers significant volume and is less effective than purified ATIII concentrate.

2. Bivalirudin: Direct Thrombin Inhibitor (DTI)

Bivalirudin is increasingly adopted as the primary anticoagulant in pediatric ECMO centers and represents the gold standard alternative for heparin resistance or Heparin-Induced Thrombocytopenia (HIT). Mechanism of Bivalirudin vs. Unfractionated Heparin:

  • [UNFRACTIONATED HEPARIN] [BIVALIRUDIN]
  • Requires Antithrombin III (Cofactor) Direct Thrombin Inhibitor (Independent of ATIII)
  • │ │
  • ▼ ▼
  • [Heparin + ATIII Complex] [Binds Free & Clot-Bound Thrombin (IIa)]
  • │ │
  • ▼ ▼
  • Inactivates Thrombin & Factor Xa Reversible inhibition of active site & exosite 1
  • (Ineffective if ATIII deficient) (Fully effective regardless of ATIII levels)

Mechanism of Action: Synthetic 20-amino-acid bivalent peptide that binds directly, specifically, and reversibly to both the catalytic active site and exosite 1 of free and clot-bound thrombin (Factor IIa) . Does not require antithrombin III.

Key Advantages over Heparin:

Complete independence from antithrombin III concentrations.

Zero cross-reactivity with anti-platelet factor 4 (PF4)/heparin antibodies; drug of choice for Heparin-Induced Thrombocytopenia (HIT) .

Inhibits clot-bound thrombin within existing microvascular thrombi.

Superior time in therapeutic range and significantly reduced circuit change frequency in pediatric clinical trials.

Dosing & Titration: Continuous infusion initiated at 0.1 to 0.3 mg/kg/h (no loading bolus in non-arrest ECMO to avoid bleeding).

Monitoring: Titrate to target aPTT of 60 to 80 seconds (or 1.5 to 2.5 times baseline), diluted thrombin time (dTT), or chromogenic anti-IIa assay.

Clearance Mechanics: 80% cleared via intravascular non-organ enzymatic proteolysis (cleaved by thrombin itself); 20% cleared via renal excretion . In severe renal dysfunction or anuria, reduce starting infusion rate to 0.05 to 0.1 mg/kg/h .